Form 4: CRISPR Therapeutics GC Reports Insider Stock Activity

CRISPR Therapeutics General Counsel James R. Kasinger reported new stock option and RSU grants, along with a tax-related sale of common shares.

Summary

• General Counsel James R. Kasinger acquired 6,250 common shares on March 20, 2026, through the vesting of a restricted stock unit award granted on March 20, 2024.
• Kasinger sold 3,182 common shares at a price of $46.78 on March 23, 2026. This sale was mandated by the Company's RSU Settlement Policy to cover tax withholding obligations related to the vesting of restricted stock units and was not a discretionary trade.
• A new grant of 38,499 stock options was awarded to Kasinger on March 20, 2026, with an exercise price of $46.24. These options will vest in 48 equal monthly installments, commencing on April 20, 2026, and have an expiration date of March 20, 2036.
• Kasinger also received a new grant of 25,000 restricted stock units on March 20, 2026. These units will vest in four equal annual installments, with the first quarter vesting on March 20, 2027, and subsequent quarters vesting on March 20, 2028, March 20, 2029, and March 20, 2030.
• Following these transactions, Kasinger directly beneficially owns 94,308 common shares, 38,499 stock options, and 37,000 restricted stock units (comprising the new 25,000 grant and 12,000 remaining from a previous grant).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as significant equity grants align executive interests with long-term company performance, despite a small, non-discretionary tax-related sale.

Positives

• The grant of 38,499 stock options and 25,000 restricted stock units aligns executive incentives with long-term shareholder value.
• The equity awards demonstrate continued compensation and retention of a key executive.

Negatives

• A sale of 3,182 common shares, even if for tax purposes, slightly reduces the executive's direct common share ownership.

Risks

• The shares acquired through vesting and the new grants remain subject to a lock-up agreement with the underwriters of the Issuer's convertible senior notes due 2031, which could restrict immediate liquidity.

Future Outlook

The filing details future vesting schedules for stock options and restricted stock units, indicating a long-term incentive structure for the General Counsel. These schedules extend through March 2030 for RSUs and March 2036 for stock options.

Management Comments

• The sale of 3,182 common shares was mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that executive compensation through equity grants, such as stock options and restricted stock units, is a standard practice in the biotechnology and pharmaceutical industries. This approach aligns executive incentives with long-term shareholder value and is crucial for talent retention in a competitive sector. The non-discretionary sale of shares to cover tax obligations upon RSU vesting is also a common and routine occurrence.

Comparison to Industry Standards

• Equity compensation packages for executives in the biotech sector, including companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals, typically feature a mix of stock options and restricted stock units with multi-year vesting schedules (often 3-5 years for RSUs and options) to ensure long-term commitment and performance alignment. The vesting schedule for CRISPR Therapeutics' grants, extending over several years, is consistent with these industry benchmarks.
• The exercise price of the granted stock options ($46.24) being close to the market price at the time of grant is a standard practice for incentive stock options, reflecting the company's valuation at the grant date.

Stakeholder Impact

• Shareholders: The significant equity grants to a key executive are designed to align management's interests with long-term shareholder value creation. The tax-related sale is a routine event and not indicative of a change in executive sentiment.
• Employees: The compensation structure reflects standard executive incentive practices within the company and the broader industry.

Next Steps

• Vesting of 38,499 stock options in 48 equal monthly installments, with the first vesting date on April 20, 2026.
• Vesting of 25,000 restricted stock units in four equal annual installments, starting March 20, 2027, and continuing through March 20, 2030.
• Further vesting of the restricted stock unit award granted on March 20, 2024, on March 20, 2027, and March 20, 2028.

Key Dates

Recommendation

This Form 4 primarily details routine executive compensation grants and a non-discretionary tax-related sale. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The grants align executive interests with long-term performance, which is generally positive, but the overall impact on the investment thesis is neutral.

Keywords

CRISPR Therapeutics, CRSP, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Executive Compensation, James R. Kasinger